Trial Profile

Phase Ib/IIa Dose Escalation and Expansion Study of [??????Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 212 Pb ADVC 001 (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; First in man
Acronyms TheraPb
Sponsors AdvanCell

Most Recent Events

03 Feb 2025 According to AdvanCell media release, AdvanCell is currently enrolling patients for the highest dose cohort of its multi-center TheraPb Ph I/II dose escalation clinical trial of ADVC001 for metastatic prostate cancer
31 Jul 2024 Planned number of patients changed from 18 to 100.
31 Jul 2024 Planned End Date changed from 1 Jun 2024 to 31 Dec 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com